Lenvatinib Mesylate
Brand name: Lenvima
Rank #111 of 500 drugs by total cost
$164.6M
Total Cost
7,004
Total Claims
$164.6M
Total Cost
387
Prescribers
$24K
Cost per Claim
130
Beneficiaries
7,080
30-Day Fills
$425K
Avg Cost/Provider
18
Avg Claims/Provider
About Lenvatinib Mesylate
Lenvatinib Mesylate (sold as Lenvima) was prescribed 7,004 times by 387 Medicare Part D providers in 2023, costing the program $164.6M. At $24K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 108 | Lifitegrast (Xiidra) | $166.6M | 149,269 |
| 109 | Alirocumab (Praluent Pen) | $165.6M | 203,805 |
| 110 | Pantoprazole Sodium (Pantoprazole Sodium) | $165.1M | 10,061,854 |
| 111 | Lenvatinib Mesylate (Lenvima) | $164.6M | 7,004 |
| 112 | Treprostinil (Tyvaso Dpi) | $158.9M | 6,704 |
| 113 | Rimegepant Sulfate (Nurtec Odt) | $155.0M | 106,692 |
| 114 | Teriparatide (Forteo) | $153.9M | 38,259 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology